This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Market And Product Forecasts: Melanoma - Yervoy Will Continue To Dominate As New Approvals Struggle To Compete

MARKET DEFINITION •Market definition for melanoma

•Forecast methodology and assumptions - Methodology flow

- Patent expiries

- New product launches

•Additional forecast methodology



AND CONTEXT•Melanoma therapies included in this report

•Current and future market dynamics overview - The branded melanoma market will experience a dramatic increase in sales over the forecast period

- Market entry of new drugs will dramatically increase the value of the branded melanoma market

- The commercial value of pipeline therapies will not surpass the total value of current marketed therapies

- New product launches will mostly impact the metastatic melanoma setting

- The US will remain the most lucrative market over the forecast period

- The overall value of branded melanoma therapies will increase across the five major EU markets

PRODUCT FORECASTS•Molecule dynamics - Yervoy will continue to dominate the melanoma market over the forecast period

•Yervoy (ipilimumab; Bristol-Myers Squibb) - Forecast assumptions

- Yervoy forecast 2012–21

•Zelboraf (vemurafenib; Roche/Daiichi Sankyo) - Forecast assumptions - Zelboraf forecast 2012–21

•Abraxane (albumin-bound paclitaxel; Celgene) - Forecast assumptions

- Abraxane forecast 2012–21

•Allovectin-7 (velimogene aliplasmid; Vical) - Forecast assumptions - Allovectin-7 forecast 2012–21

•Dabrafenib (GSK-2118436; GlaxoSmithKline) - Forecast assumptions

- Dabrafenib forecast 2012–21

•MAGE-A3 ASCI (astuprotimut-r; GlaxoSmithKline) - Forecast assumptions - MAGE-A3 ASCI forecast 2012–21

•OncoVEX GM-CSF (talimogene laherparepvec; Amgen) - Forecast assumptions

- OncoVEX forecast 2012–21

•POL-103A (Polynoma/CK Life Sciences) - Forecast assumptions - POL-103A forecast 2012–21

•Trametinib (GSK-1120212; GlaxoSmithKline) - Forecast assumptions

- Trametinib forecast 2012–21 BIBLIOGRAPHY

•Journal papers•Websites APPENDIX

•Forecast methodology - Volume and value forecast methodology- Price and compliance assumptions TABLES

•Table: Summary of therapeutic classes in melanoma by ATC code, 2012•Table: Patent expiry dates for key marketed brands in melanoma, 2012•Table: Estimated launch dates for key late-stage pipeline products in melanoma, 2012–21•Table: Drugs included in melanoma market and product forecasts, 2012–21•Table: Melanoma drug sales in the US and five major EU markets ($m), 2012–21•Table: Melanoma drug sales in the US ($m), 2012–21•Table: Melanoma molecule sales in the five major EU markets ($m), 2012–21•Table: Key melanoma drug sales in the US and five major EU markets, 2012 and 2021•Table: Yervoy sales, by country ($m), 2012–21•Table: Yervoy patients, by country, 2012–21•Table: Zelboraf sales, by country ($m), 2012–21•Table: Zelboraf patients, by country, 2012–21•Table: Abraxane sales, by country ($m), 2012–21•Table: Abraxane patients, by country, 2012–21•Table: Allovectin-7 sales, by country ($m), 2012–21•Table: Allovectin-7 patients, by country, 2012–21•Table: Dabrafenib sales, by country ($m), 2012–21•Table: Dabrafenib patients, by country, 2012–21•Table: MAGE-A3 ASCI sales, by country ($m), 2012–21•Table: MAGE-A3 ASCI patients, by country, 2012–21•Table: OncoVEX GM-CSF sales, by country ($m), 2012–21•Table: OncoVEX GM-CSF patients, by country, 2012–21•Table: POL-103A sales, by country ($m), 2012–21•Table: POL-103A patients, by country, 2012–21•Table: Trametinib sales, by country ($m), 2012–21•Table: Trametinib patients, by country, 2012–21•Table: Price sources and calculations, by country, 2012•Table: Exchange rates used for calculating prices, 2012 FIGURES

•Figure: Patient-based forecast methodology for melanoma, 2012•Figure: Melanoma market forecast across the US and five major EU markets, by country ($m), 2012–21•Figure: Melanoma sales in the US and five major EU markets, by class ($m), 2012–21•Figure: Estimated approval/launch dates of key melanoma therapies, 2012–21•Figure: Branded melanoma market value in the US, by drug class ($m), 2012–21•Figure: Branded melanoma market value in the five major EU markets, by drug class ($m), 2012–21•Figure: Key branded melanoma drug sales, 2012–21•Figure: Yervoy sales, by country ($m), 2012–21•Figure: Zelboraf sales, by country ($m), 2012–21•Figure: Abraxane sales, by country ($m), 2012–21•Figure: Allovectin-7 sales, by country ($m), 2012–21•Figure: Dabrafenib sales, by country ($m), 2012–21•Figure: MAGE-A3 ASCI sales, by country ($m), 2012–21•Figure: OncoVEX GM-CSF sales, by country ($m), 2012–21•Figure: POL-103A sales, by country ($m), 2012–21•Figure: Trametinib sales, by country ($m), 2012–21

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs